tiprankstipranks
MacroGenics (MGNX)
NASDAQ:MGNX

MacroGenics Stock Analysis & Ratings

MGNX Stock Chart & Stats

Day’s Range$4.08 - $4.29
52-Week Range$3.96 - $32.81
Previous Close$4.19
Volume847.53K
Average Volume (3M)670.42K
Market Cap$255.15M
P/E Ratio-1.2
Beta2.10
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score8
EPS (TTM)-3.56


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

MGNX FAQ

What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was $3.96 and its highest was $32.81 in the past 12 months.
    What is MacroGenics’s market cap?
    MacroGenics’s market cap is $255.15M.
      What is MacroGenics’s price target?
      The average price target for MacroGenics is $26.88. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $50.00 ,the lowest forecast is $15.00. The average price target represents 546.15% Increase from the current price of $4.16.
        What do analysts say about MacroGenics?
        MacroGenics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
          When is MacroGenics’s upcoming earnings report date?
          MacroGenics’s upcoming earnings report date is Aug 03, 2022 which is in 79 days.
            How were MacroGenics’s earnings last quarter?
            MacroGenics released its earnings results on May 03, 2022. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.849 by -$0.231.
              Is MacroGenics overvalued?
              According to Wall Street analysts MacroGenics’s price is currently Undervalued.
                Does MacroGenics pay dividends?
                MacroGenics does not currently pay dividends.
                What is MacroGenics’s EPS estimate?
                MacroGenics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does MacroGenics have?
                MacroGenics has 61,330,000 shares outstanding.
                  What happened to MacroGenics’s price movement after its last earnings report?
                  MacroGenics reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.849. Following the earnings report the stock price went down -16.903%.
                    Which hedge fund is a major shareholder of MacroGenics?
                    Among the largest hedge funds holding MacroGenics’s share is RA Capital Management. It holds MacroGenics’s shares valued at 98M.

                      ---

                      MacroGenics Stock Analysis

                      Smart Score
                      8
                      Outperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $26.88
                      ▲(546.15% Upside)
                      Strong Buy
                      The MacroGenics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      MacroGenics

                      MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Pfizer
                      Eli Lilly & Co
                      Johnson & Johnson
                      Gilead Sciences
                      Bristol Myers

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis